later. 4 , 11 , 12 CD19 CAR T-Cell Therapy and Disease Management Leukemias Prognosis and overall survival (OS) rates in adult and pediatric patients with relapsed and refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. 13 – 15
Search Results
Chimeric Antigen Receptor T-Cell Therapy
Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J. Fry, Morgan Garber, Rebecca A. Gardner, Lauren Gurschick, Patricia Kropf, Jeff J. Reitan, Craig Sauter, Bijal Shah, Elizabeth J. Shpall, and Steven T. Rosen
Chemotherapy in the Management of Osteosarcoma and Ewing's Sarcoma
Scott M. Schuetze
. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity . N Engl J Med 1986 ; 314 : 1600 – 1606 . 19. Rosen G Caparros B Huvos AG . Preoperative chemotherapy for osteogenic sarcoma
Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors
Jerald P. Radich and Vivian Oehler
phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse . Leukemia 2005 ; 19 : 507 – 512 . 21. Merx K Muller MC Kreil S . Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic
Advancements in Radiation Techniques for Gastric Cancer
Matthew D. Callister and Leonard L. Gunderson
early locoregional relapse and attempt surgical resection and salvage. Local disease relapse was seen in 67% of patients, and 88% of these had a component of local or regional failure. In addition, 50% of peritoneal failures were localized to the
Defining and Managing High-Risk Multiple Myeloma: Current Concepts
Luciano J. Costa and Saad Z. Usmani
7 molecular subgroups of NDMM, 9 3 of which were described as having the highest risk of early relapse: the MMSET gene overexpression, MAF / MAFB overexpression, and proliferative gene overexpression subgroups. The Arkansas group also developed
Use of Biomarkers and Multigene Assays in Breast Cancer
Lee S. Schwartzberg
, they can stratify patients into lower and higher risk of later relapse between years 5 through 10 after diagnosis. The Breast Cancer Index also appears to have some predictive value for prolonged endocrine therapy. As a fundamental change, the latest
Analysis of Circulating Tumor Cells in Breast Cancer
Zeynep Eroglu, Odicie Fielder, and George Somlo
Through coordinated scientific, medical, and public health advances, 5-year survival rates for breast cancer approach 90%. However, microscopic residual disease frequently results in local relapse or metastasis, leading to approximately 40
Novel Targets for Therapeutic Agents in Small Cell Lung Cancer
Patrick C. Ma and Ravi Salgia
. N901-blocked ricin for relapsed small-cell lung cancer . Chest 1993 ; 103 : 436S – 439S . 60 Lynch TJ Jr Lambert JM Coral F . Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin . J Clin Oncol 1997
Optimizing Endocrine Therapy for Breast Cancer
Amelia B. Zelnak and Ruth M. O'Regan
improved outcomes for patients with all stages of hormone receptor (HR)–positive breast cancer. However, despite the marked success of endocrine therapy in the treatment of HR-positive breast cancers, many patients will experience relapse and all patients
Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials
Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza
investigators pooled estimates for distant metastases, visceral recurrences, and occurrence rate of locoregional relapses. Considering that treatment outcomes may vary among different types of bisphosphonates, the investigators performed subgroup analyses for
